湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-008 湖南方盛制药股份有限公司 关于公司参与投资设立的并购基金对外出售投资 项目部分股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、同系方盛已于近期召开合伙人会议，同意将其存续期延长一年至 2027 年 1 月 31 日，同意同系泰兴、同系未来将其分别持有的同系方盛未实缴出资额 31.70 万元（实缴 出资 28.30 万元）、285.30 万元退伙（实缴出资 254.70 万元），同系方盛认缴出资额由 47,065.83 万元减少为 46,748.83 万元； 2、根据此前约定，同系方盛在收回全部回购款项后不再持有湖南珂信股权；此外， 目前武汉珂信 6%的股权已过户至同系方盛名下； 3、根据湖南珂信提供的长沙珂信相关数据，长沙珂信 2025 年度扣除非经常性损益 后的净利润已达到向盈康生命作出的首年业绩承诺目标，预计将触 ...

湖南方盛制药股份有限公司 关于公司《药品生产许可证》变更的公告 湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-007 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）近期完成 了《药品生产许可证》的变更登记并取得了湖南省药品监督管理 局核发的《药品生产许可证》。现将相关情况公告如下： 一、《药品生产许可证》的变更内容 1、在生产地址湖南省长沙市麓松路 789 号新增生产范围： 贴剂（仅用于注册申报），所在车间生产线：贴膏剂一车间贴剂 生产线 1，上述剂型及车间生产线通过药品 GMP 符合性检查后 方可生产上市； 2、新增生产范围：原料药盐酸替扎尼定、盐酸乙哌立松， 仅用于注册申报，所在车间生产线：原料药一车间原料药生产线 1，上述品种转 A 并通过药品 GMP 符合性检查后方可生产上市。 二、变更后的《药品生产许可证》具体内容 许可证编号：湘 20150028 企业名 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 关于受让药品上市许可的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2025 年 3 月 25 日，湖南方盛制药股份有限公司（以下简称 "公司"）受让康溢医药有限公司（以下简称"康溢医药"）持 有的"喉咽清胶囊""浙贝止咳露（黄盒）"等合计 20 个在香 港特别行政区卫生署（以下简称"香港卫生署"）注册的药品品 种的所有权（详见公司 2025-030 号公告）；2025 年 6 月 3 日， 公司与自然人赵国灏先生、港捷有限公司（以下简称"港捷公司"）、 湖南科祺创新科技有限公司（以下简称"科祺创新"）与湖南筱 沐医药科技有限公司（以下简称"筱沐医药"）签订《投资合作 协议》，调整对香港合资子公司的股权结构（详见公司 2025-060 号公告）；2025 年 6 月 20 日，公司与康溢医药、自然人李明志 先生签订《药品品种转让协议之补充协议》，决定对《药品品种 转让协议 ...

方盛制药公告称，2026年1月28日，香港合资子公司香港方盛堂与相关方签订补充协议，新增注册资本 4500万港元，公司认购2705万港元，增资后持股比例由50%增至57%。除港捷公司外，各方根据生产经 营需求分期同比例实缴出资。目前，香港方盛堂正分批次对受让的20个药品品种进行技术升级，受让药 品变更手续在准备办理中。此次增资对公司经营及药品许可转让交易无重大影响，但药品内地上市注册 及后续研究评价、生产销售等存在不确定性。 ...

Group 1 - Spot gold price has surpassed $5000 per ounce for the first time, with institutions predicting it could rise to $6600 [2] - The recent surge in gold prices is attributed to U.S. President Trump's policies reshaping international relations and investors fleeing sovereign bonds and foreign exchange markets [2] - Last week, gold prices increased by 8.5%, driven by a weakening dollar, which has made gold and silver cheaper for global buyers [2] Group 2 - In the past two weeks, stock ETFs have seen a net outflow of nearly 500 billion yuan, with significant redemptions in broad-based ETFs [3] - The trading volume of stock ETFs has surged, with some broad-based ETFs reaching record highs since their inception [3] Group 3 - The semiconductor sector in A-shares has been active in mergers and acquisitions, with several companies announcing related plans and progress [8] Group 4 - The commercial aerospace sector is experiencing a talent shortage, with investors with relevant experience being highly sought after [9] - The market is facing a significant gap in experienced commercial aerospace investors, leading firms to recruit candidates with adjacent experience [9] Group 5 - Global commodity markets are entering a new super cycle, with fund managers strategically increasing allocations to non-ferrous and chemical products [10] - Factors such as global monetary expansion, a credit crisis in the dollar, and geopolitical conflicts are contributing to this anticipated cycle [10]

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].

（编辑 丛可心） 证券日报网讯 1月25日，方盛制药发布公告称，2026年1月23日，公司全资子公司广东方盛健盟药业有 限公司收到国家药品监督管理局核准签发的洛索洛芬钠凝胶贴膏《药品注册证书》，规格每贴 14cm×10cm含膏体10g、洛索洛芬钠100mg，用于骨关节炎等镇痛消炎，已获国药准字H20263068，无 需一致性评价。 ...

洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿胀疼痛的消炎、镇痛，有效成分为洛索洛芬 钠，属苯丙酸类非甾体抗炎药（NSAID），具有显著的抗炎镇痛作用，尤以镇痛效果为强。本品由 LEADCHEMICALCO.LTD.原研开发，是我国市场长期销量领先的镇痛类药物之一，其作用机制为抑制 前列腺素合成，通过抑制环氧化酶发挥作用。洛索洛芬钠为前体药物，经皮吸收后转化为活性代谢产物 反式-OH体起效。 格隆汇1月25日丨方盛制药(603998.SH)公布，公司全资子公司广东方盛健盟药业有限公司（称"健盟药 业"）收到国家药品监督管理局核准签发的《药品注册证书》，洛索洛芬钠凝胶贴膏已获得药品批准文 号并可进行生产。 ...

方盛制药1月25日公告，2026年1月23日，公司全资子公司广东方盛健盟药业有限公司收到国家药品监督 管理局核准签发的《药品注册证书》，洛索洛芬钠凝胶贴膏已获得药品批准文号并可进行生产。截至本 公告日，国内共有15家企业取得了洛索洛芬钠凝胶贴膏的药品注册证书，其中上市公司为九典制药 （300705）、达仁堂（600329）、华润三九（000999），其他厂家属于非上市公司。 ...